Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Hiroaki Wakimoto, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Hiroaki Wakimoto and Hiroko Wakimoto.
Connection Strength

1.302
  1. Wakimoto H, Fulci G, Tyminski E, Chiocca EA. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther. 2004 Jan; 11(2):214-23.
    View in: PubMed
    Score: 0.310
  2. Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 2003 Jun; 10(11):983-90.
    View in: PubMed
    Score: 0.298
  3. Wakimoto H, Maguire CT, Kovoor P, Hammer PE, Gehrmann J, Triedman JK, Berul CI. Induction of atrial tachycardia and fibrillation in the mouse heart. Cardiovasc Res. 2001 Jun; 50(3):463-73.
    View in: PubMed
    Score: 0.259
  4. Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S, Tamaki M, Hirakawa K. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer. 1996 Jan 15; 77(2):373-80.
    View in: PubMed
    Score: 0.179
  5. Ning JF, Stanciu M, Humphrey MR, Gorham J, Wakimoto H, Nishihara R, Lees J, Zou L, Martuza RL, Wakimoto H, Rabkin SD. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nat Commun. 2019 07 02; 10(1):2910.
    View in: PubMed
    Score: 0.057
  6. Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther. 2006 Apr; 13(8):705-14.
    View in: PubMed
    Score: 0.023
  7. Deisboeck TS, Wakimoto H, Nestler U, Louis DN, Sehgal PK, Simon M, Chiocca EA, Hochberg FH. Development of a novel non-human primate model for preclinical gene vector safety studies. Determining the effects of intracerebral HSV-1 inoculation in the common marmoset: a comparative study. Gene Ther. 2003 Aug; 10(15):1225-33.
    View in: PubMed
    Score: 0.019
  8. Tanaka M, Berul CI, Ishii M, Jay PY, Wakimoto H, Douglas P, Yamasaki N, Kawamoto T, Gehrmann J, Maguire CT, Schinke M, Seidman CE, Seidman JG, Kurachi Y, Izumo S. A mouse model of congenital heart disease: cardiac arrhythmias and atrial septal defect caused by haploinsufficiency of the cardiac transcription factor Csx/Nkx2.5. Cold Spring Harb Symp Quant Biol. 2002; 67:317-25.
    View in: PubMed
    Score: 0.017
  9. Nagashima G, Aoyagi M, Yamamoto S, Wakimoto H, Tamaki M, Yamamoto K, Fujimoto T, Hirakawa K. Involvement of disregulated c-myc but not c-sis/PDGF in atypical and anaplastic meningiomas. Clin Neurol Neurosurg. 2001 Apr; 103(1):13-8.
    View in: PubMed
    Score: 0.016
  10. Ikeda K, Wakimoto H, Ichikawa T, Jhung S, Hochberg FH, Louis DN, Chiocca EA. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol. 2000 May; 74(10):4765-75.
    View in: PubMed
    Score: 0.015
  11. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, Harsh GR, Louis DN, Bartus RT, Hochberg FH, Chiocca EA. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 1999 Aug; 5(8):881-7.
    View in: PubMed
    Score: 0.014
  12. Nagashima G, Aoyagi M, Yamamoto M, Yamamoto S, Wakimoto H, Ohno K, Yamamoto K, Hirakawa K. P53 overexpression and proliferative potential in malignant meningiomas. Acta Neurochir (Wien). 1999; 141(1):53-61; discussion 60-1.
    View in: PubMed
    Score: 0.014
  13. Hara M, Aoyagi M, Nagashima G, Wakimoto H, Mikami T, Yamamoto S, Tamaki M, Hirakawa K. Recurrence in meningeal hemangiopericytomas. Surg Neurol. 1998 Dec; 50(6):586-91.
    View in: PubMed
    Score: 0.014
  14. Takada Y, Ohno K, Wakimoto H, Hirakawa K. Treatment of intracranial abscess in the era of neuroimaging: an analysis of 13 consecutive cases. J Med Dent Sci. 1998 Jun; 45(2):69-76.
    View in: PubMed
    Score: 0.013
  15. Kanai F, Lan KH, Shiratori Y, Tanaka T, Ohashi M, Okudaira T, Yoshida Y, Wakimoto H, Hamada H, Nakabayashi H, Tamaoki T, Omata M. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 1997 Feb 01; 57(3):461-5.
    View in: PubMed
    Score: 0.012
  16. Tanaka T, Kanai F, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Shiratori Y, Lan K, Ishitobi M, Omata M. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res. 1996 Mar 15; 56(6):1341-5.
    View in: PubMed
    Score: 0.011
  17. Aoyagi M, Yamamoto M, Wakimoto H, Azuma H, Hirakawa K, Yamamoto K. Immunohistochemical detection of Ki-67 in replicative smooth muscle cells of rabbit carotid arteries after balloon denudation. Stroke. 1995 Dec; 26(12):2328-31; discussion 2331-2.
    View in: PubMed
    Score: 0.011
  18. Nagashima G, Aoyagi M, Wakimoto H, Tamaki M, Ohno K, Hirakawa K. Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas. Neurosurgery. 1995 Sep; 37(3):478-82; discussion 483.
    View in: PubMed
    Score: 0.011
  19. Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H. Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol. 1995; 121(9-10):587-92.
    View in: PubMed
    Score: 0.010
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.